GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Change In Payables And Accrued Expense

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Change In Payables And Accrued Expense : $3.61 Mil (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Change In Payables And Accrued Expense?

Frazier Lifesciences Acquisition's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2022 was $1.97 Mil. It means Frazier Lifesciences Acquisition's Accounts Payable & Accrued Expense increased by $1.97 Mil from Jun. 2022 to Sep. 2022 .

Frazier Lifesciences Acquisition's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2021 was $-0.01 Mil. It means Frazier Lifesciences Acquisition's Accounts Payable & Accrued Expense declined by $0.01 Mil from Dec. 2020 to Dec. 2021 .

Frazier Lifesciences Acquisition Change In Payables And Accrued Expense Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Change In Payables And Accrued Expense Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Change In Payables And Accrued Expense
- -0.01

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only 0.13 -0.02 -0.07 1.73 1.97

Frazier Lifesciences Acquisition Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frazier Lifesciences Acquisition Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
OMEG LJAQ GSQB PRBM MURF ITAQ APCA JATT SGII MEPW GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Website
https://www.frazierlifesciencesacquisition.com
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830